Cogstate Depression Battery

Assess cognitive function in subjects with clinically diagnosed Major Depressive Disorder (MDD).

Cogstate’s computerized battery of rapid, reliable, simple and sensitive tests measure the cognitive domains affected by MDD: processing speed, attention, visual learning, working memory, visual motor function and executive function.

The construct validity of each test for cognitive impairment in MDD as well as the sensitivity of these test to change in cognition has been demonstrated in the scientific literature. The tests have also been shown to be valid for use in different cultures and language groups with comparative/normative data available for both clinical samples and healthy controls. Study teams wishing to measure all or a subset of these domains can choose the tests that best suit their specific research questions. Each of the tests have been utilized previously in drug trials and maintain excellent reliability across repeated testing and cross-sectional research designs.

Cogstate Tests

Detection Test

The Detection test measures processing speed using a simple reaction time paradigm.

Learn More

Identification Test

The Identification test measures attention using a choice reaction time paradigm.

Learn More

One Card Learning Test

The One Card Learning test measures visual memory using a pattern separation paradigm.

Learn More

One Back Test

The One Back test measures working memory using an n-back paradigm.

Learn More

Groton Maze Learning Test

The Groton Maze Learning Test measures executive function using a maze learning paradigm.

Learn More

Battery Details

Length:Between 5-20 minutes
(depending on the number of tests included in the battery*)
Administration:Standardized
Data Processing and Scoring:Automated
Application:Phase I-IV
Culture and Language Neutral:Yes

Learn More About Computerized Assessment

Key References

McIntyre, R. S., Lophaven, S., Olsen, C. K. (2014). A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. International Journal of Neuropsychopharmacology, 17(10), 1557-1567. doi: 10.1017/S1461145714000546.

Olver, J. S., Ignatiadis, S., Maruff, P., Burrows, G. D., and Norman, T. R., (2008) Quetiapine augmentation in depressed patients with partial response to antidepressants. Human  Psychopharmacology Clinical and Experimental; 23: 653–660.

Shiroma, P.R., Albott, C.S., Johns, B., Thuras, P., Wels, J., & Lim, K. O. (2014). Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. International Journal of Neuropsychopharmacology, 17(11), 1805-1813. doi: 10.1017/S1461145714001011

Yoshida, T., Ishikawa, M., Niitsu, T., Nakazato, M., Watanabe, H., Shiraishi, T., … Hashimoto, K. (2012). Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One, 7(8). doi: 10.1371/journal.pone.0042676